Medizone International, Inc. (OTCMKTS:MZEI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
press release announcing the completion of its study that
demonstrates the efficacy of AsepticSure in killing
microorganisms found in preparation rooms within funeral homes.
This announcement opens up the death care industry as a viable
commercial segment in the United States and other key markets in
the world. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K. The information in this
Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed
filed for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release dated June 8, 2017.
|
About Medizone International, Inc. (OTCMKTS:MZEI)
Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company’s AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system’s formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms.